7 research outputs found
In vitro and in vivo comparison between poractant alfa and the new generation synthetic surfactant CHF5633.
Get PDFCHF5633 is a new generation synthetic surfactant containing both SP-B and SP-C analogues developed for the treatment of respiratory distress syndrome. Here, the optimal dose and its performance in comparison to the animal-derived surfactant poractant alfa were investigated
In vitro and in vivo comparison between poractant alfa and the new generation synthetic surfactant CHF5633
No full textRegular energy drink consumption is associated with the risk of health and behavioural problems in adolescents
No full textTherapeutic Effect of Intravenous Infusion of Perfluorocarbon Emulsion on LPS-Induced Acute Lung Injury in Rats
No full text
